To identify the microglial-released factors involved in the stimulation of cell proliferation through FAK and Pyk2 signaling, glioma cells were treated with previously selected cytokines/chemokines, including EGF, IL-6, IL-8, SDF-1α, PDGFα, PDGFβ, or MCM in combination with one of their respective blockers (gefitinib, tocilizumab, reparixin, burixafor, inhibitor III, or DMPQ, respectively). The gene discussed is CXCL12; the disease is central nervous system cancer.